Gurugram. A suspected fake drug racket operating under the name of diabetes medication Mounjaro has been exposed in Gurugram after the Haryana Food and Drug Administration seized a large consignment of suspected counterfeit medicines. The products were allegedly being manufactured and sold illegally in the market at inflated prices, prompting concern over patient safety and pharmaceutical supply chain oversight.
Counterfeit Products Found During FDA Raid
According to information, the enforcement action was carried out nearly two weeks ago in Gurugram, where officials uncovered an organised network dealing in Mounjaro QuickPen-style products. Preliminary findings suggest that the operation was being run without a valid licence, regulatory approval or quality control checks.
FCRF Academy Launches Premier Anti-Money Laundering Certification Program
During the raid, officials recovered a substantial stock of suspected counterfeit medicines being marketed as treatment for diabetes patients. Authorities noted that the packaging and labelling were highly similar to the original product, making it difficult for ordinary consumers to identify fake versions.
Eli Lilly Says Seized Drugs Were Not Authorised
Eli Lilly, the global pharmaceutical company associated with Mounjaro, has extended support to the enforcement action. In its statement, the company clarified that the seized products were not part of its authorised supply chain.
The company said Mounjaro is manufactured and distributed only through a controlled and certified system involving licensed distributors and authorised pharmacies. It also stated that the counterfeit products had no direct or indirect link with its legitimate supply operations.
Patient Safety Concerns Come Into Focus
Eli Lilly described counterfeit medicines as a serious criminal issue, warning that such products may pose major risks to patients. The company said fake drugs may lack the correct amount of active ingredients, which can lead to treatment failure or serious health complications.
Health experts have also cautioned that consumption of fake medicines can be dangerous because their quality and composition cannot be guaranteed. The incident has prompted renewed concern among patients and healthcare professionals about sourcing medicines only through verified channels.
Investigations and monitoring efforts have been intensified. Authorities are now focused on ensuring that only certified and safe medicines reach the market, while the case has highlighted the need for tighter oversight in the pharmaceutical supply chain.
